Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2023

Sophia Antipolis, France

Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2023, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares18,404,608
Number of real voting rights* (excluding treasury shares**)18,353,180
Theoretical number of voting rights* (including treasury shares**)18,381,408
(*) Class E preference share are non-voting – (**) Pursuant to article 223-11 of the AMF’s General Regulations
Download 20240108_PR_shares_votingrights_Dec2023.pdf

About Median Technologies

Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer and metabolic disease diagnoses and treatments. Median’s offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. Since its inception, the French-based company, with a presence in the U.S. and China, has been recognized as an “Innovative company” by BPI France and trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).

 

Contacts

Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ggasparetto@actifin.fr